OPKO Health CEO Buys ~200K Shares
OPKO Health (OPK) reported Q2 EPS of ($0.14), $0.15 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $309.9 million versus the consensus estimate of...
Investing.com – Israel stocks were lower after the close on Tuesday, as losses in the Banking, Biomed and Financials sectors led shares lower. At the close in Tel Aviv, the TA 35...
DexCom, Inc.’s DXCM second-quarter 2020 adjusted earnings of 79 cents per share surpassed the Zacks Consensus Estimate of 31 cents by 154.8%. Notably, the company reported...
OPKO Health, Inc. (NASDAQ:OPK) recently announced that its subsidiary — BioReference Laboratories — has collaborated with the City of Detroit to provide coronavirus...
OPKO Health, Inc. (OPK) recently announced that its subsidiary — BioReference Laboratories — has collaborated with the state of New Jersey to provide coronavirus...
OPKO Health, Inc. is a healthcare company. The Company’s segments include Diagnostics and Pharmaceutical. The Diagnostics segment consists of the clinical laboratory operations of Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health) and GeneDx. Its Pharmaceutical Business have one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Oxyntomodulin, Biologics, Factor VIIa -CTP and hGH-CTP. It also owns an active pharmaceutical ingredients (APIs) manufacturer in Israel through its subsidiary FineTech Pharmaceutical, Ltd.
|Average||6.50 (+240.31% Upside)|
|No. of Analysts||4|